{ "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-12T11:34:59Z", "providers": [ "Codex" ], "breadth": "recalled by Codex without web access - no source was read", "missingProviders": [], "pass": 2, "cost": { "grok": { "seconds": 16.1, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a09565-1c9a-7402-a8b3-454dc8884de8\n--------\nuser\nDescribe what is already known about one registered thing. Answer as JSON only, no prose around it.\n\nThing: nicomorphine\nSense to describe: (none recorded)\nDomain code: PHY.MAT\nAlso known as: (none)\n\n\nContext for this batch of 1001 things:\n# Batch 044: 1001 re", "usd": 0.0, "recall": true }, "codex": { "seconds": 72.8, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a09565-1c8c-7d02-bcf1-3c89ddef47f3\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: nicomorphine\nRegistry id: vr.tr.nicomorphine\nPlane / domain: PHY / PHY.MAT\nRegistry definition: (none recorded)\nNames folded into this entry: (none)\n" } }, "enrichment": { "pass": 3, "engine": "claude", "producedAt": "2026-10-06T12:00:00Z", "ingestedAt": "2026-10-06T08:51:29+00:00", "fields": [ "agent_conduct", "ethics", "failure_modes_and_hazards", "owners", "standards_and_regulation", "visual_identification" ] }, "gate": { "passed": true, "version": "1.0", "at": "2026-10-07T10:10:32+00:00", "evidence": [ "completeness 1.00", "sense: Wikidata description", "2 live sources", "review by codex: pass" ] } }, "metaModel": { "id": "THING-Q7030497", "registryId": "vr.tr.nicomorphine", "name": "nicomorphine", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "PHY.MAT" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q7030497/", "model": { "registry_id": "vr.tr.nicomorphine", "name": "nicomorphine", "purpose": "Enable an agent to identify nicomorphine, assess the identity and condition of a material containing it, and determine which handling or analytical actions are supported by evidence and applicable controls.", "definition": "Nicomorphine is a semisynthetic opioid derived from morphine by esterifying its two hydroxyl groups with nicotinic acid, forming morphine 3,6-dinicotinate.", "scope_statement": "This model owns nicomorphine as the chemical substance registered at vr.tr.nicomorphine in PHY / PHY.MAT, including molecular identity, material form, composition, stability, analytical recognition, biological transformation relationships, and substance-specific handling constraints.", "in_scope": [ "Nicomorphine molecular structure, stereochemistry, names, and verified identifiers", "Distinction between parent substance, salt forms, and quantified nicomorphine content", "Batch purity, related substances, physical state, and storage-dependent condition", "Analytical identification and differentiation from structurally related opioids", "Metabolite relationships and evidence needed to interpret detection", "Evidence-backed hazard information and jurisdiction-specific substance controls" ], "out_of_scope": [ "Finished medicinal products, excipient systems, packaging, and marketing authorizations", "Patient-specific prescribing, dosing, treatment selection, and clinical management", "Manufacturing routes and operational synthesis procedures", "Independent models of morphine, nicotinic acid, and nicomorphine metabolites", "Laboratory equipment design and complete analytical standard operating procedures" ], "distinguishing_features": [ "Verify morphine bearing nicotinoyl ester groups at both the 3- and 6-oxygen positions; this distinguishes nicomorphine from morphine and either mono-nicotinoylmorphine.", "Confirm pyridine-3-carbonyl ester groups rather than the acetyl groups of diamorphine or another pyridinecarbonyl positional arrangement.", "Confirm the morphine stereochemical framework and nitrogen substitution rather than accepting a shared molecular formula or similar opioid name.", "Resolve the parent compound separately from hydrochloride or other material forms before comparing formulas, identifiers, masses, or assay results.", "Require evidence specific to intact nicomorphine when distinguishing its presence from detection of morphine or a related transformation product." ], "characteristics": [ { "name": "Parent molecular identity", "kind": "category", "unit_or_values": "Structure with stereochemistry; parent formula C29H25N3O5; PubChem CID 5362460", "why_it_matters": "Anchors the registry entry to a defined compound rather than a product name; identity reference: [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Nicomorphine)." }, { "name": "Material form", "kind": "category", "unit_or_values": "Free base or identified salt; counterion, stoichiometry, hydration and solvation recorded separately", "why_it_matters": "Determines which formula, mass conversion, and physical-property evidence apply." }, { "name": "Nicomorphine assay", "kind": "measurement", "unit_or_values": "% by mass or mg/g; specify as-is, dried, anhydrous, salt, or parent-equivalent basis", "why_it_matters": "Makes purity and quantity comparisons interpretable across batches and forms." }, { "name": "Related-substance profile", "kind": "measurement", "unit_or_values": "Individual impurity concentrations in % by mass, mg/g, or explicitly qualified chromatographic area %", "why_it_matters": "Separates intact nicomorphine from monoesters, morphine, and unidentified components." }, { "name": "Physical and thermal behavior", "kind": "measurement", "unit_or_values": "Phase at stated temperature and pressure; melting or decomposition interval in °C; boiling point only if experimentally meaningful", "why_it_matters": "Prevents transferring constants between salt forms or treating decomposition as boiling." }, { "name": "Solubility under specified conditions", "kind": "measurement", "unit_or_values": "mg/mL or mol/L with solvent, pH, temperature, and material form", "why_it_matters": "Supports defensible decisions about sampling and analytical preparation." }, { "name": "Sample integrity", "kind": "state", "unit_or_values": "Unassessed, supported within specified conditions, suspected alteration, or confirmed alteration", "why_it_matters": "Distinguishes the identity on a label from the substance currently present." }, { "name": "Transformation relationships", "kind": "relation", "unit_or_values": "Parent-to-product links with biological or nonbiological context and supporting evidence", "why_it_matters": "Keeps metabolism, storage degradation, and preparation artifacts distinct." }, { "name": "Hazard and control status", "kind": "category", "unit_or_values": "Source-specific hazard classification, exposure-limit status, and jurisdiction/date-specific legal classification", "why_it_matters": "Supports handling and access decisions without treating missing evidence as absence of risk or restriction." } ], "affordances": [ "Reconcile a nicomorphine label or registry record with verified structural identifiers and material form.", "Compare batches using assay results expressed on a consistent parent or salt basis.", "Assess whether analytical evidence distinguishes intact nicomorphine from related opioids and transformation products.", "Flag material whose impurity profile or storage history leaves its present condition uncertain.", "Identify documented requirements for authorized storage, transfer, analysis, and disposal in a specified jurisdiction." ], "agent_conduct": { "may": [ "Identify nicomorphine by name, identifiers and its controlled status, citing official sources.", "Report where it has medical use and under what controls, from official sources." ], "must_not": [ "Assist anyone to make, obtain, convert or use it outside lawful medical channels.", "Give dosing, routes of use or ways to boost or combine its effects.", "Help evade controls on opioids, such as prescriptions, import rules or testing.", "Recommend it for any particular person's pain." ], "requires_human": [ "Any handling, transfer or destruction of controlled stocks.", "Reporting a suspected diversion to authorities." ] }, "ethics": { "considerations": [ "As a morphine derivative it carries strong risks of dependence and fatal overdose.", "Pain relief must stay available to patients while diversion is prevented." ], "affected_parties": [ "Patients needing strong pain relief", "People at risk of overdose", "Families and communities" ] }, "owners": { "steward": "Licensed holders under national drug control law; the national drug control authority regulates it.", "master_systems": [ "National controlled substances registers" ] }, "visual_identification": [ "Identity can only be settled by laboratory analysis and official documentation.", "Lawful products carry licensed labels and are kept in controlled storage." ], "failure_modes_and_hazards": [ "Breathing depression and overdose.", "Dependence and withdrawal.", "Diversion from medical supply to illicit use." ], "standards_and_regulation": [ "Single Convention on Narcotic Drugs, 1961, United Nations, under which it is internationally controlled." ], "what_it_is_for": [ "Nicomorphine is an opioid analgesic encountered in medical literature and pharmaceutical contexts involving treatment of severe pain.", "It is also relevant to forensic and toxicological analysis where morphine derivatives must be distinguished." ] }, "sources": [ { "id": "wikidata", "title": "Wikidata item Q7030497: nicomorphine", "url": "https://www.wikidata.org/wiki/Q7030497", "url_status": "live", "what_it_supports": "identity and sense of the item", "checked_by": "wikidata-api" }, { "id": "wikipedia-en", "title": "Wikipedia: Nicomorphine", "url": "https://en.wikipedia.org/wiki/Nicomorphine", "url_status": "live", "what_it_supports": "general description of the item", "checked_by": "wikidata-api sitelink" } ], "structure": { "bundles": [ { "id": "molecular-identity-and-boundaries", "name": "Molecular identity and boundaries", "description": "Establish which chemical entity the nicomorphine name denotes and prevent confusion with related structures or material forms.", "rationale": "A morphine derivative, its monoesters, and its salts cannot share unqualified identity or property records.", "layers": [ { "id": "dinicotinoyl-structure", "name": "Dinicotinoyl structure", "description": "Recognize the substitution pattern and stereochemical identity of the parent compound.", "findings": [ { "id": "parent-structure-anchor", "name": "Parent structure anchor", "description": "Anchor the entry to a stereochemically specified structure and verified identifier record; [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Nicomorphine) supplies a starting identity reference.", "questions": [ { "text": "Which verified structure establishes both morphine oxygen positions as nicotinoyl esters and specifies the stereochemistry?", "kind": "definition", "id": "parent-structure-anchor-q01" }, { "text": "Which CAS number, InChIKey, and other identifiers resolve to that exact parent structure rather than a salt or related monoester?", "kind": "provenance", "id": "parent-structure-anchor-q02" } ] } ] }, { "id": "parent-and-material-forms", "name": "Parent and material forms", "description": "Relate supplied forms to nicomorphine without equating the substance with its medicinal products.", "findings": [ { "id": "form-specific-records", "name": "Form-specific records", "description": "Record counterion, stoichiometry, and hydration separately, attaching each identifier and property to the form actually described.", "questions": [ { "text": "Does the material contain free-base nicomorphine, an identified salt, or a mixture whose form is unresolved?", "kind": "definition", "id": "form-specific-records-q01" }, { "text": "Which names refer to the chemical entity, and which refer to formulations or trade products requiring separate models?", "kind": "boundary", "id": "form-specific-records-q02" } ] } ] } ] }, { "id": "composition-and-physical-state", "name": "Composition and physical state", "description": "Characterize the quantity, purity, and physical behavior of a particular nicomorphine material.", "rationale": "Salt content, water, and related substances can make nominally identical nicomorphine samples materially different.", "layers": [ { "id": "assay-and-related-substances", "name": "Assay and related substances", "description": "Express nicomorphine content and impurity evidence on explicit measurement bases.", "findings": [ { "id": "comparable-composition", "name": "Comparable composition", "description": "Keep parent-equivalent content, salt mass, water content, and analytical peak proportions distinct.", "questions": [ { "text": "What is the measured nicomorphine content, and is it reported as parent equivalent or as the identified material form?", "kind": "measurement", "id": "comparable-composition-q01" }, { "text": "Which mono-nicotinoylmorphines, morphine, residual solvents, or unidentified impurities were measured, and with what uncertainty?", "kind": "measurement", "id": "comparable-composition-q02" } ] } ] }, { "id": "form-dependent-properties", "name": "Form-dependent properties", "description": "Attach physical constants to the tested form and experimental conditions.", "findings": [ { "id": "qualified-property-evidence", "name": "Qualified property evidence", "description": "Record measured phase, thermal behavior, and solubility without substituting predictions or values from another form.", "questions": [ { "text": "What phase and melting or decomposition behavior were measured for the identified form, at what pressure and with which method?", "kind": "measurement", "id": "qualified-property-evidence-q01" }, { "text": "What solubility measurements apply to that form at the recorded solvent composition, pH, and temperature?", "kind": "measurement", "id": "qualified-property-evidence-q02" } ] } ] } ] }, { "id": "analytical-recognition-and-integrity", "name": "Analytical recognition and integrity", "description": "Determine whether a sample contains intact nicomorphine and whether handling has altered the evidence.", "rationale": "A related opioid signal or an altered sample can support an incorrect identity conclusion.", "layers": [ { "id": "selective-identification", "name": "Selective identification", "description": "Establish the specificity of evidence used to recognize nicomorphine.", "findings": [ { "id": "orthogonal-identity-evidence", "name": "Orthogonal identity evidence", "description": "Assess reference-standard matching and complementary structural evidence against relevant confounders.", "questions": [ { "text": "Which reference-standard comparison and spectral or structural observations support intact nicomorphine identification?", "kind": "measurement", "id": "orthogonal-identity-evidence-q01" }, { "text": "Can the method distinguish nicomorphine from monoesters, diamorphine, and compounds with similar mass or chromatographic behavior?", "kind": "boundary", "id": "orthogonal-identity-evidence-q02" } ] } ] }, { "id": "handling-dependent-integrity", "name": "Handling-dependent integrity", "description": "Evaluate changes between collection, storage, preparation, and measurement.", "findings": [ { "id": "alteration-assessment", "name": "Alteration assessment", "description": "Treat ester cleavage and other possible changes as evidence questions tied to actual sample conditions.", "questions": [ { "text": "What stability evidence covers nicomorphine in this matrix under the recorded temperature, pH, light exposure, and elapsed time?", "kind": "provenance", "id": "alteration-assessment-q01" }, { "text": "Do repeat measurements or controls show loss of parent compound or formation of related substances during storage or preparation?", "kind": "measurement", "id": "alteration-assessment-q02" } ] } ] } ] }, { "id": "biological-transformation-and-interpretation", "name": "Biological transformation and interpretation", "description": "Link nicomorphine to relevant biological products while preserving limits on exposure interpretation.", "rationale": "Parent detection and metabolite detection answer different questions about nicomorphine exposure.", "layers": [ { "id": "documented-metabolite-links", "name": "Documented metabolite links", "description": "Record biological transformation relationships with study context.", "findings": [ { "id": "contextualized-metabolism", "name": "Contextualized metabolism", "description": "Research identifies 6-nicotinoylmorphine and morphine as biologically active metabolites; rates and detectability require contextual evidence. See the [primary metabolite study](https://pubmed.ncbi.nlm.nih.gov/34528849/).", "questions": [ { "text": "Which metabolites are experimentally established, in which species and biological matrices?", "kind": "provenance", "id": "contextualized-metabolism-q01" }, { "text": "Which route, sampling times, and analytical conditions support any reported parent disappearance or metabolite appearance rates?", "kind": "measurement", "id": "contextualized-metabolism-q02" } ] } ] }, { "id": "attribution-limits", "name": "Attribution limits", "description": "Assess what a biological finding can establish about the parent substance.", "findings": [ { "id": "exposure-specificity", "name": "Exposure specificity", "description": "Separate detection of an analyte from attribution to nicomorphine and from conclusions about clinical effect.", "questions": [ { "text": "Which detected analytes or combinations have validated specificity for nicomorphine exposure rather than another source of morphine?", "kind": "boundary", "id": "exposure-specificity-q01" }, { "text": "What additional evidence is required before reporting nicomorphine exposure when intact parent compound is absent?", "kind": "action", "id": "exposure-specificity-q02" } ] } ] } ] }, { "id": "hazards-and-permitted-handling", "name": "Hazards and permitted handling", "description": "Connect the identified nicomorphine material to substantiated hazards and current handling requirements.", "rationale": "Chemical hazard classification, opioid effects, and legal controls require distinct evidence and may apply differently to material forms.", "layers": [ { "id": "material-specific-hazards", "name": "Material-specific hazards", "description": "Establish the hazard evidence relevant to the supplied form and likely exposure.", "findings": [ { "id": "qualified-hazard-record", "name": "Qualified hazard record", "description": "Record applicable safety documentation and distinguish an established classification from an unassessed hazard.", "questions": [ { "text": "Which safety data sheet or authoritative assessment covers this nicomorphine form, and what classifications does it substantiate?", "kind": "provenance", "id": "qualified-hazard-record-q01" }, { "text": "Are substance-specific occupational exposure limits established, and what documented handling measures apply when those limits are unavailable?", "kind": "action", "id": "qualified-hazard-record-q02" } ] } ] }, { "id": "jurisdictional-controls", "name": "Jurisdictional controls", "description": "Determine requirements for a specified location, date, material form, and proposed activity.", "findings": [ { "id": "activity-specific-authorization", "name": "Activity-specific authorization", "description": "Attach legal conclusions to current authoritative instruments rather than inferring them from therapeutic classification or historical availability.", "questions": [ { "text": "Which current legal provisions explicitly cover nicomorphine and its salts in the relevant jurisdiction?", "kind": "provenance", "id": "activity-specific-authorization-q01" }, { "text": "What authorization, custody records, storage conditions, and disposal arrangements are required for the proposed activity?", "kind": "action", "id": "activity-specific-authorization-q02" } ] } ] } ] }, { "id": "evidence-and-external-alignment", "name": "Evidence and external alignment", "description": "What the world already says about this thing, gathered so the model can be checked against it.", "rationale": "A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.", "layers": [ { "id": "reported-evidence", "name": "Reported evidence", "description": "Findings from the breadth pass, kept separate from the structural claims.", "findings": [ { "id": "evidence-confidence-notes", "name": "Check these first", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "This account is recalled knowledge; no sources were consulted.", "Verify registry identifiers, salt forms, and measured physical properties before populating those fields.", "Verify present medicinal availability and controlled-substance status separately for each jurisdiction." ], "questions": [ { "id": "evidence-confidence-notes-q01", "text": "Which of these check these first hold for the sense of nicomorphine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-identifiers", "name": "Identifiers and schemes", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "scheme": "Chemical structural nomenclature", "value_or_pattern": "morphine 3,6-dinicotinate", "note": "Describes the two nicotinic-acid ester groups attached to morphine." } ], "questions": [ { "id": "evidence-identifiers-q01", "text": "Which of these identifiers and schemes hold for the sense of nicomorphine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-real-world-use", "name": "Real-world use", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Has been used medicinally as an opioid analgesic for severe pain." ], "questions": [ { "id": "evidence-real-world-use-q01", "text": "Which of these real-world use hold for the sense of nicomorphine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-failure-modes-and-hazards", "name": "Failure modes and hazards", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Respiratory depression, potentially fatal in overdose.", "Sedation and impaired alertness.", "Tolerance, physical dependence, and withdrawal.", "Constipation, nausea, and vomiting.", "Increased risk of profound sedation and respiratory depression when combined with alcohol or other central nervous system depressants." ], "questions": [ { "id": "evidence-failure-modes-and-hazards-q01", "text": "Which of these failure modes and hazards hold for the sense of nicomorphine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-neighbours", "name": "Neighbouring kinds and how to tell them apart", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "name": "morphine", "difference": "Morphine has free hydroxyl groups at positions 3 and 6; nicomorphine has nicotinate esters at both positions." }, { "name": "diamorphine", "difference": "Diamorphine is morphine's 3,6-diacetate; nicomorphine is its 3,6-dinicotinate." }, { "name": "nicotinic acid", "difference": "Nicotinic acid supplies the ester groups but lacks nicomorphine's morphine skeleton and opioid identity." } ], "questions": [ { "id": "evidence-neighbours-q01", "text": "Which of these neighbouring kinds and how to tell them apart hold for the sense of nicomorphine this model covers, and on what evidence?", "kind": "provenance" } ] } ] } ] } ] }, "openQuestions": [ "Which CAS and EC identifiers are verified for the parent and each relevant salt, hydrate, or solvate, and which apparent synonym records conflate these forms?", "Which primary measurements establish form-specific melting or decomposition behavior, solubility, and storage stability; is a boiling point experimentally meaningful?", "Which validated methods and reference materials distinguish intact nicomorphine from positional monoesters and quantify changes during sample handling?", "Which biological markers reliably attribute exposure to nicomorphine, and how do route, matrix, and sampling time limit that attribution?", "Which current jurisdiction-specific controls, material-specific GHS classifications, and occupational exposure limits are supported by authoritative records?" ], "statistics": { "bundles": 6, "layers": 11, "findings": 15, "questions": 25 } }